MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Evolus Cash Conversion Cycle 2011-2026 | EOLS
Annual Cash Conversion Cycle Evolus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.8 | 74.6 | 94.9 | 62.9 | 0.17 | -62.4 | 139 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 139 | -62.4 | 54.9 |
Quarterly Cash Conversion Cycle Evolus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90.7 | 56.9 | 56.6 | - | 75.5 | 60.7 | 66.9 | - | 107 | 127 | 137 | - | 72.1 | 9.24 | 13.7 | - | 10.2 | -27 | -90.4 | - | -67.7 | -180 | 27.3 | - | 88.9 | 505 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 505 | -180 | 57 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
55.1 | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-38 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-4.1 K | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-227 | $ 6.15 | 2.84 % | $ 91.4 M | USA |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
61.7 | $ 2.83 | -0.53 % | $ 1.09 B | Canada |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
-46.2 | $ 35.07 | -0.9 % | $ 1.29 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
110 | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
79.8 | $ 5.31 | -1.85 % | $ 1.97 B | Canada |
 |
Pacira BioSciences
PCRX
|
209 | $ 23.38 | -1.27 % | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
106 | $ 2.56 | -2.29 % | $ 324 M | USA |
 |
Canopy Growth Corporation
CGC
|
177 | $ 1.07 | -4.46 % | $ 115 M | Canada |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 3.6 | -2.04 % | $ 197 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
150 | $ 1.16 | 4.05 % | $ 1.44 M | USA |
 |
Jupiter Wellness
JUPW
|
-186 | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
169 | $ 5.51 | -2.57 % | $ 3.41 B | Canada |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.14 | 0.37 % | $ 109 M | Canada |
 |
Emergent BioSolutions
EBS
|
360 | $ 9.2 | 0.22 % | $ 492 M | USA |
 |
Veru
VERU
|
19.6 | $ 2.34 | 0.65 % | $ 34.3 M | USA |
 |
cbdMD
YCBD
|
83 | $ 0.78 | -5.56 % | $ 3.14 M | USA |
 |
Assertio Holdings
ASRT
|
467 | $ 23.44 | -0.02 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
96 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-35 | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
2.74 | $ 0.71 | -3.07 % | $ 35.5 M | USA |
 |
PLx Pharma
PLXP
|
113 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
150 | $ 16.05 | -0.37 % | $ 18.7 B | USA |
 |
Zomedica Corp.
ZOM
|
154 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
57 | $ 0.74 | -2.11 % | $ 26.6 M | USA |
 |
China Pharma Holdings
CPHI
|
139 | $ 0.8 | 2.81 % | $ 3.43 M |  China |
 |
TherapeuticsMD
TXMD
|
-723 | $ 2.04 | -3.32 % | $ 23.6 M | USA |